Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...
England’s cost effectiveness body NICE has recommended GSK’s new severe asthma treatment Nucala, reversing an earlier decision to reject it. Nucala (mepolizumab) is the first biologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback